Skye Bioscience, Inc. (SKYE)
1.80
+0.02
(+1.12%)
USD |
NASDAQ |
Sep 04, 16:00
1.80
0.00 (0.00%)
After-Hours: 16:27
Skye Bioscience Cash from Operations (Annual) : -43.06M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -43.06M |
| December 31, 2024 | -25.24M |
| December 31, 2023 | -13.95M |
| December 31, 2022 | -12.74M |
| December 31, 2021 | -6.475M |
| December 31, 2020 | -6.054M |
| December 31, 2019 | -6.028M |
| December 31, 2018 | -3.943M |
| Date | Value |
|---|---|
| December 31, 2017 | -3.331M |
| December 31, 2016 | -3.553M |
| December 31, 2015 | -3.690M |
| December 31, 2014 | -1.755M |
| October 31, 2013 | -0.0145M |
| October 31, 2012 | 0.0019M |
| October 31, 2011 | -0.004M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 4.979B |
| Viking Therapeutics, Inc. | -278.68M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |
| Anika Therapeutics, Inc. | 11.19M |